Advertisement
Screener

ARS Pharmaceuticals, Inc. (SPRY) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

ARS Pharmaceuticals, Inc. Cash Flow Breakdown

Cash flow breakdown shows where ARS Pharmaceuticals, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $170.87M went out.
  • Fiscal year ended 2025-12-31: from investing, $56.77M came in.
  • Fiscal year ended 2025-12-31: from financing, $104.60M came in.
  • Fiscal year ended 2025-12-31: change in cash, $9.50M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingNew debtNot split outChange in cash
2025-12-31-$170.87M$56.77M$96.26M$8.34M*-$9.50M
2024-12-31$13.55M-$106.10M$0.00$72.40M*-$20.15M
2023-12-31-$59.27M-$87.18M$6.90M*-$139.55M
2022-12-31-$40.08M-$199.00K$190.73M*$150.46M
2021-12-31-$17.56M-$55.00K$53.16M*$35.54M
2020-12-31-$31.20M-$917.00K$408.51M*

Each quarter (3 month)

Quarter endRunning the businessFrom investingNew debtNew shares soldNot split outChange in cash
2026-06-30-$60.93M*$41.57M*$3.20M*
2026-03-31-$44.95M$27.79M-$17.00M
2025-12-31-$43.48M*$24.11M*-$1.49M*$2.62M*
2025-09-30-$47.05M*-$44.98M*$100.05M*
2025-06-30-$39.59M*$48.57M*$2.70M*
2025-03-31-$40.74M$29.06M$725.00K*-$10.95M
2024-12-31$42.00M*-$101.76M*$0.00*$70.92M*
2024-09-30-$14.47M*$16.82M*$680.00K*
2024-06-30-$7.28M*-$12.65M*$545.00K*
2024-03-31-$6.71M-$8.51M-$14.96M
2023-12-31-$17.41M*$26.04M*$1.80M*
2023-09-30-$12.76M*-$46.64M*$921.00K*
2023-06-30-$16.67M*$44.97M*$2.85M*
2023-03-31-$12.43M-$111.55M$1.32M*-$122.66M
2022-12-31-$20.50M*-$126.00K*$193.82M*
2022-09-30-$5.68M*-$30.00K*-$1.56M*
2022-06-30-$6.97M*-$22.00K*-$623.00K*
2022-03-31-$6.92M-$21.00K-$908.00K*-$7.85M
2021-12-31$27.89M*$40.74M*$52.82M*
2021-09-30-$19.12M*-$40.06M*
2021-06-30-$14.13M*-$700.00K*
2021-03-31-$12.20M-$35.00K
2020-12-31-$11.10M*-$247.00K*$255.40M*
2020-09-30-$7.03M*-$632.00K*$119.86M*
2020-06-30-$5.44M*-$5.00K*$11.93M*
2020-03-31-$7.63M-$33.00K$6.00K$21.31M*

Similar stocks

Stock NameCountryMarket CapPE Ratio
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85